News

AstraZeneca, along with its biologics research and development arm MedImmune, has secured approval from the Japanese ministry of health, labour and welfare for Imfinzi (durvalumab) as maintenance therapy

The agreements have a combined value of $5.9 million and these projects are expected to be substantially completed within a 15-month period. Telix is a biopharmaceutical company specializing

These therapeutic antibodies include ‘blood-brain barrier (BBB)’ penetrating bispecific antibodies (BsAb) (VEGF/undisclosed BBB target BsAb, undisclosed target/undisclosed BBB target BsAb); immune cell engaging bispecific antibodies (4-1BB/undisclosed target BsAb,

AstraZeneca, along with its biologics research and development arm MedImmune, has secured approval from the Japanese ministry of health, labour and welfare for Imfinzi (durvalumab) as maintenance therapy

CVC Fund VII has agreed to acquire holding company, FIMEI, which owns a 51% stake in Recordati. The consortium is comprised of PSP Investments and StepStone. FIMEI chairman and

According to the American Heart Association, more than 900,000 people are diagnosed with heart failure every year in the United States. The condition, which results from the failure

The chemotherapy used in combination with Tecentriq is Abraxane [albumin-bound paclitaxel; nab-paclitaxel]). The late-stage trial dubbed IMpassion130 was found to have reduced the risk of disease worsening or

The European Commission will review the CHMP recommendation and a final decision on the Marketing Authorisation Application for Cablivi in the European Union is expected in the coming

The companies announced that they had entered into exclusive talks on April 17, 2018. The signing of this Share Purchase Agreement marks a critical step on the way